GLP-1s and Appetite Hormones: Leptin and Ghrelin

GLP-1 is only one voice in a noisy hormonal conversation about hunger. Two of the better-known others are ghrelin, often called the hunger hormone, and leptin, the signal of energy sufficiency from fat tissue. People starting GLP-1 medications often want to know how the drug fits alongside these, and whether it fixes the frustrating ways appetite hormones usually fight back against weight loss.

The short version: GLP-1 drugs act powerfully on appetite, but they don’t override the rest of the system, and understanding that helps set realistic expectations.

The cast of hormones

Ghrelin rises before meals and tends to climb when you lose weight, nudging you to eat more, one reason diets are so hard to sustain. Leptin signals fullness over the longer term, but it falls as fat mass falls, and the brain reads that drop as a reason to increase hunger and conserve energy.

GLP-1 itself is a gut-derived hormone that promotes satiety and slows gastric emptying. The medications amplify this signaling well beyond natural levels.

The key nuance: GLP-1 drugs add a strong, sustained satiety signal that helps counterbalance the body’s pushback during weight loss, but the underlying ghrelin and leptin responses to losing weight don’t vanish. The drug helps you ride over them, not erase them.

What the controlled data shows

The satiety effect is well documented. In a 2021 trial published in Diabetes, Obesity and Metabolism, Friedrichsen and colleagues randomized 72 adults with obesity to semaglutide 2.4 mg or placebo for 20 weeks. Ad libitum energy intake was 35% lower with semaglutide (1736 vs 2676 kJ; P < 0.0001), and participants reported reduced hunger, increased fullness and satiety, and better control of eating with fewer cravings. Notably, that trial measured appetite ratings, not hormone levels; it does not directly prove anything about ghrelin or leptin.

The leptin question has its own dedicated study. In a 2015 International Journal of Obesity trial, 52 adults lost weight and then entered a 52-week maintenance phase on either the GLP-1 agonist liraglutide (1.2 mg) or control. During maintenance, the fall in free leptin was about 43% smaller with liraglutide, and the rise in soluble leptin receptor was 59% lower, a proposed mechanism for preserving leptin signaling. Ghrelin levels, by contrast, did not differ between the groups.

What this means in practice

• Appetite drops noticeably because the GLP-1 signal is loud and constant, which is the central reason intake falls.
• The body still adapts to weight loss with hormonal changes that favor regain, part of why stopping the medication often brings appetite, and weight, back.
• The leptin signal is partly protected, but ghrelin doesn’t appear to be reset in that trial; the data on exactly how these hormones shift is still limited and not fully clean.

Why the interaction is still being mapped

It’s tempting to draw a tidy diagram of GLP-1 turning ghrelin down and leptin sensitivity up. Reality is messier. The controlled human data shows a real effect on leptin during weight maintenance but no clear ghrelin change, individual responses vary, and much of what’s claimed online is more confident than the evidence supports. Treat precise mechanistic stories with healthy skepticism.

The takeaway

GLP-1 medications work mostly by adding a strong satiety signal that helps counter the hunger-promoting hormonal shifts that normally accompany weight loss: in controlled trials, cutting energy intake by about a third and blunting the leptin drop during maintenance. They don’t switch ghrelin off, which is part of why the body tends to push back when treatment stops. Knowing that the other hormones are still in the room makes both the results and the limits easier to understand.

Sources

• The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity (Diabetes, Obesity and Metabolism, 2021)
• Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss (International Journal of Obesity, 2015)